Medical device company Penumbra (NYSE:PEN) reported in Q4 CY2024, with sales up 10.8% year on year to $315.5 million. On the ...

Looking back on medical devices & supplies - cardiology, neurology, vascular stocks’ Q3 earnings, we examine this quarter’s ...

Penumbra is actively working with regulatory and reimbursement bodies in Europe, Asia-Pacific and Latin America to bring the entire CAVT portfolio to patients internationally. The company expects ...

The patient was on two antihypertensive medications and a statin, and she was not receiving any antiplatelet medication. She was taken by ambulance to a primary stroke center. Initial examination ...